PEGPH20 Could Improve Metastatic Pancreatic Cancer Outcomes

Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma.

Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Pancreatic Cancer Source Type: news